The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
The Clinical Significance of Epidermal Growth Factor Receptor (EGF-R) in Human Breast Cancer: A Review on 5232 Patients*
Open accessAbstract
EGF-R positivity was shown to be present in 2500 (48%) of 5232 breast tumors in 40 different series of patients. The mean of the percentages of EGF-R positivity in the individual series reported by these 40 different groups of investigators is 45% (range 14-91%). Overall there are generally no clear differences between results obtained by radioligand binding assays, immunological methods, autoradiography, and measurement of EGF-R transcripts although the mean percentage of EGF-R-positive tumors determined by immunological methods tends to be somewhat lower. Nearly all studies indicate a negative relationship between EGF-R and steroid receptor status (28 of 31 studies for ER, 12/19 for PR) showing that EGF-R positivity is twice as high in ER or PR- negative tumors compared to ER or PR- positive tumors (approximately 50-60% vs. 30%). With regard to other prognostic factors the majority of investigators (10/18) also reported a significant (positive) correlation with tumor grade, but only a minority found a significant relationship between EGF-R status and patient age (2/9), menopausal status (1/7), histological type (3/7), tumor size (2/17), nodal status (5-9/20), ploidy (1/7), or proliferation indices (3/9). No relationship was observed with tumor insulin-like growth factor I receptor, PRL receptor (PRL-R), and LHRH receptor (LHRH-R) status, but an inverse relationship between EGF-R and somatostatin receptor may be present. However, it has to be stressed that the series in which the relationship between EGF-R status and other prognostic factors were investigated, contained relatively few patients (mostly less than 100). Therefore, when larger groups of patients are investigated, more significant relationships may be observed, especially with respect to nodal status, tumor ploidy, and proliferation indices. In fact, we calculated the presence of EGF-R positivity overall in 35% of 253 aneuploid tumors vs. in only 15% of 114 diploid tumors (P less than 0.0001). In addition most studies observed a trend, if no significant correlation, between higher EGF-R levels in tumors with the highest percentages of S-phase or Ki-67 expression. With regard to relapse-free and overall survival, five of nine different groups of investigators showed significant prognostic value of EGF-R after short-term (1- to 4-yr) follow-up, indicating that patients with EGF-R-positive tumors have a poor prognosis. However, three of five groups with a maximal follow-up of at least 6 yr found only a tendency for any relationship between EGF-R status and long-term outcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Carpenter, G., & Cohen, S. (1979) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.48.070179.001205 · Cited by 2,909
The neu oncogene encodes an epidermal growth factor receptor-related protein
Bargmann, C. I., Hung, M.-C., & Weinberg, R. A. (1986) · Nature · doi:10.1038/319226a0 · Cited by 1,117
Richard, J., Sainsbury, C., Needham, G., Farndon, J., Malcolm, A., & Harris, A. (1987) · The Lancet · doi:10.1016/s0140-6736(87)90593-9 · Cited by 892
Autophosphorylation sites on the epidermal growth factor receptor
Downward, J., Parker, P., & Waterfield, M. D. (1984) · Nature · doi:10.1038/311483a0 · Cited by 704
Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer.
Wright, C., Angus, B., Nicholson, S., Sainsbury, J. R. C., Cairns, J., Gullick, W. J., Kelly, P., Harris, A. L., & Horne, C. H. W. (1989) · PubMed · Cited by 622
Neal, D., Bennett, M., Hall, R., Marsh, C., Abel, P., Sainsbury, J. R. C., & Harris, A. (1985) · The Lancet · doi:10.1016/s0140-6736(85)91386-8 · Cited by 604
EPIDERMAL-GROWTH-FACTOR RECEPTORS AND OESTROGEN RECEPTORS IN HUMAN BREAST CANCER
Sainsbury, J. R. C., Sherbet, G. V., Farndon, J. R., & Harris, A. L. (1985) · The Lancet · doi:10.1016/s0140-6736(85)91385-6 · Cited by 492
Metabolism and Effects of Epidermal Growth Factor and Related Growth Factors in Mammals*
FISHER, D. A., & LAKSHMANAN, J. (1990) · Endocrine Reviews · doi:10.1210/edrv-11-3-418 · Cited by 374
Role of epidermal growth factor in carcinogenesis.
Stoscheck, C. M., & King, L. E. (1986) · PubMed · Cited by 325
Follow-up study of HER-2/neu amplification in primary breast cancer.
Clark, G. M., & McGuire, W. L. (1991) · PubMed · Cited by 261
Hillner, B. E., & Smith, T. J. (1991) · New England Journal of Medicine · doi:10.1056/nejm199101173240305 · Cited by 237
Sainsbury, J. R., Malcolm, A. J., Appleton, D. R., Farndon, J. R., & Harris, A. L. (1985) · Journal of Clinical Pathology · doi:10.1136/jcp.38.11.1225 · Cited by 226
Nicholson, S., Halcrow, P., Farndon, J., Sainsbury, J. R. C., Chambers, P., & Harris, A. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91202-6 · Cited by 218
Pekonen, F., Partanen, S., Mäkinen, T., & Rutanen, E. ‐. (1988) · PubMed · Cited by 208
Fitzpatrick, S. L., LACHANCE, M. P., & Schultz, G. S. (1984) · PubMed · Cited by 201
Fekete, M., Wittliff, J. L., & Schally, A. V. (1989) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.1860030302 · Cited by 200
Lacroix, H., Iglehart, J. D., Skinner, M. A., & Kraus, M. H. (1989) · PubMed · Cited by 162
Zeillinger, R., Kury, F., Czerwenka, K. F., Kubista, E., Sliutz, G., Knogler, W., Huber, J., Zielinski, C. C., Reiner, G. C. A., & Jakesz, R. (1989) · PubMed · Cited by 150
Nicholson, S., Wright, C., Sainsbury, J. R. C., et al. (1990) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(90)90424-j · Cited by 145
4. The role of the epidermal growth factor receptor and the c-erbB-2 protein in breast cancer
Gullick, W. J. (1990) · International Journal of Cancer · doi:10.1002/ijc.2910460708 · Cited by 128
Foekens, J. A., Portengen, H., Janssen, M., & Klijn, J. G. M. (1989) · Cancer · Cited by 116
Self-citationTranscripts for transforming growth factors in human breast cancer: clinical correlates
Barrett-Lee, P. J., Travers, M. T., Luqmani, Y. A., & Coombes, R. C. (1990) · British Journal of Cancer · doi:10.1038/bjc.1990.136 · Cited by 104
Koenders, P. G., Beex, L. V. A. M., Geurts-Moespot, A. J., Heuvel, J. J. T. M., Kienhuis, C. B. M., & Benraad, T. J. (1991) · PubMed · Cited by 81
Prognostic value of epidermal growth factor receptor in node-positive breast cancer
Grimaux, M., Romain, S., Remvikos, Y., Martin, P., & Magdelénat, H. (1989) · Breast Cancer Research and Treatment · doi:10.1007/bf01805978 · Cited by 69
Prognostic significance of the receptor for epidermal growth factor in human mammary carcinomas.
Macias, A., Azavedo, E., Hägerström, T., Klintenberg, C., Pérez, R., & Skoog, L. K. (1987) · PubMed · Cited by 62
Delarue, J. C., Friedman, S., Mouriesse, H., May-Levin, F., Sancho-Garnier, H., & Contesso, G. (1988) · Breast Cancer Research and Treatment · doi:10.1007/bf01805841 · Cited by 57
Clinical breast cancer, new developments in selection and endocrine treatment of patients
Klijn, J. G. M., Berns, P. M. J. J., Bontenbal, M., et al. (1992) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(92)90210-a · Cited by 46
Self-citationWalker, R. A., & Camplejohn, R. S. (1986) · The Journal of Pathology · doi:10.1002/path.1711500107 · Cited by 41
Fernandez‐Pol, J. A., Klos, D. J., & Hamilton, P. D. (1989) · Journal of Cellular Biochemistry · doi:10.1002/jcb.240410306 · Cited by 34
Stimulatory and inhibitory growth factors and breast cancer
Dickson, R. B. (1990) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(90)90422-h · Cited by 24
Grimaux, M., Mady, E., Remvikos, Y., Lainé‐Bidron, C., & Magdelénat, H. (1990) · International Journal of Cancer · doi:10.1002/ijc.2910450209 · Cited by 22
Cited by
Epidermal growth factor-related peptides and their receptors in human malignancies
Salomon, D. S., Brandt, R., Ciardiello, F., & Normanno, N. (1995) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(94)00144-i · Cited by 2,690
Nicholson, R. I., Gee, J. M. W., & Harper, M. E. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00231-3 · Cited by 2,143
Epidermal growth factor receptor (EGFR) signaling in cancer
Normanno, N., De Luca, A., Bianco, C., Strizzi, L., Mancino, M., Maiello, M. R., Carotenuto, A., De Feo, G., Caponigro, F., & Salomon, D. S. (2006) · Gene · doi:10.1016/j.gene.2005.10.018 · Cited by 2,038
Structural basis for inhibition of the epidermal growth factor receptor by cetuximab
Li, S., Schmitz, K. R., Jeffrey, P. D., Wiltzius, J. J. W., Kussie, P., & Ferguson, K. M. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.003 · Cited by 1,118
Wadas, T. J., Wong, E. H., Weisman, G. R., & Anderson, C. J. (2010) · Chemical Reviews · doi:10.1021/cr900325h · Cited by 924
Metadata
- Authors
- KLIJN, J. G. M., BERNS, P. M. J. J., SCHMITZ, P. I. M., & FOEKENS, J. A.
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 1992-02
- Volume
- 13
- Issue
- 1
- Pages
- 3-17
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W2081625464
- Cited by
- 597
- References
- 32
- FWCI
- 12.80
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.